Literature DB >> 25103488

Does universal active MRSA surveillance influence anti-MRSA antibiotic use? A retrospective analysis of the treatment of patients admitted with suspicion of infection at Veterans Affairs Medical Centers between 2005 and 2010.

Makoto Jones1, Benedikt Huttner2, Molly Leecaster2, Angela Huttner2, Kavitha Damal2, Windy Tanner3, Christopher Nielson4, Michael A Rubin2, Matthew Bidwell Goetz5, Karl Madaras-Kelly6, Matthew H Samore2.   

Abstract

OBJECTIVES: After the implementation of an active surveillance programme for MRSA in US Veterans Affairs (VA) Medical Centers, there was an increase in vancomycin use. We investigated whether positive MRSA admission surveillance tests were associated with MRSA-positive clinical admission cultures and whether the availability of surveillance tests influenced prescribers' ability to match initial anti-MRSA antibiotic use with anticipated MRSA results from clinical admission cultures.
METHODS: Analyses were based on barcode medication administration data, microbiology data and laboratory data from 129 hospitals between January 2005 and September 2010. Hospitalized patient admissions were included if clinical cultures were obtained and antibiotics started within 2 days of admission. Mixed-effects logistic regression was used to examine associations between positive MRSA admission cultures and (i) admission MRSA surveillance test results and (ii) initial anti-MRSA therapy.
RESULTS: Among 569,815 included admissions, positive MRSA surveillance tests were strong predictors of MRSA-positive admission cultures (OR 8.5; 95% CI 8.2-8.8). The negative predictive value of MRSA surveillance tests was 97.6% (95% CI 97.5%-97.6%). The diagnostic OR between initial anti-MRSA antibiotics and MRSA-positive admission cultures was 3.2 (95% CI 3.1-3.4) for patients without surveillance tests and was not significantly different for admissions with surveillance tests.
CONCLUSIONS: The availability of nasal MRSA surveillance tests in VA hospitals did not seem to improve the ability of prescribers to predict the necessity of initial anti-MRSA treatment despite the high negative predictive value of MRSA surveillance tests. Prospective trials are needed to establish the safety and effectiveness of using MRSA surveillance tests to guide antibiotic therapy. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  definitive treatment; empirical treatment; vancomycin

Mesh:

Substances:

Year:  2014        PMID: 25103488      PMCID: PMC4296187          DOI: 10.1093/jac/dku299

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

1.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

2.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Diekema; M A Pfaller; F J Schmitz; J Smayevsky; J Bell; R N Jones; M Beach
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

3.  Transmission of resistant bacteria in intensive care.

Authors:  Stephen J Seligman
Journal:  N Engl J Med       Date:  2011-08-25       Impact factor: 91.245

4.  Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections.

Authors:  Rajiv Jain; Stephen M Kralovic; Martin E Evans; Meredith Ambrose; Loretta A Simbartl; D Scott Obrosky; Marta L Render; Ron W Freyberg; John A Jernigan; Robert R Muder; LaToya J Miller; Gary A Roselle
Journal:  N Engl J Med       Date:  2011-04-14       Impact factor: 91.245

5.  Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.

Authors:  Xavier Bertrand; Michael J Dowzicky
Journal:  Clin Ther       Date:  2011-12-09       Impact factor: 3.393

6.  Parenteral to oral conversion of fluoroquinolones: low-hanging fruit for antimicrobial stewardship programs?

Authors:  Makoto Jones; Benedikt Huttner; Karl Madaras-Kelly; Kevin Nechodom; Christopher Nielson; Matthew Bidwell Goetz; Melinda M Neuhauser; Matthew H Samore; Michael A Rubin
Journal:  Infect Control Hosp Epidemiol       Date:  2012-04       Impact factor: 3.254

7.  An antibiotic care bundle approach based on results of rapid molecular screening for nasal carriage of methicillin-resistant Staphylococcus aureus in the intensive care unit.

Authors:  Paola Stano; Manuela Avolio; Rita De Rosa; Maria Luisa Modolo; Stefano M M Basso; Franco Lumachi; Alessandro Camporese
Journal:  In Vivo       Date:  2012 May-Jun       Impact factor: 2.155

8.  Health care-associated invasive MRSA infections, 2005-2008.

Authors:  Alexander J Kallen; Yi Mu; Sandra Bulens; Arthur Reingold; Susan Petit; Ken Gershman; Susan M Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; William Schaffner; Priti R Patel; Scott K Fridkin
Journal:  JAMA       Date:  2010-08-11       Impact factor: 56.272

9.  Surveillance cultures for detection of methicillin-resistant Staphylococcus aureus: diagnostic yield of anatomic sites and comparison of provider- and patient-collected samples.

Authors:  Ebbing Lautenbach; Irving Nachamkin; Baofeng Hu; Neil O Fishman; Pam Tolomeo; Priya Prasad; Warren B Bilker; Theoklis E Zaoutis
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

10.  A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia.

Authors:  John M Boyce; Olivia-Fabiola Pop; Odaliz Abreu-Lanfranco; Whitney Y Hung; Ann Fisher; Afshin Karjoo; Benjamin Thompson; Zenon Protopapas
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

View more
  3 in total

1.  Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia.

Authors:  Barbara Ellen Jones; Jian Ying; Vanessa Stevens; Candace Haroldsen; Tao He; McKenna Nevers; Matthew A Christensen; Richard E Nelson; Gregory J Stoddard; Brian C Sauer; Peter M Yarbrough; Makoto M Jones; Matthew Bidwell Goetz; Tom Greene; Matthew H Samore
Journal:  JAMA Intern Med       Date:  2020-04-01       Impact factor: 21.873

2.  Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010.

Authors:  Barbara E Jones; Makoto M Jones; Benedikt Huttner; Gregory Stoddard; Kevin Antoine Brown; Vanessa W Stevens; Tom Greene; Brian Sauer; Karl Madaras-Kelly; Michael Rubin; Matthew Bidwell Goetz; Matthew Samore
Journal:  Clin Infect Dis       Date:  2015-07-29       Impact factor: 9.079

3.  A Methyl 4-Oxo-4-phenylbut-2-enoate with in Vivo Activity against MRSA that Inhibits MenB in the Bacterial Menaquinone Biosynthesis Pathway.

Authors:  Joe S Matarlo; Yang Lu; Fereidoon Daryaee; Taraneh Daryaee; Bela Ruzsicska; Stephen G Walker; Peter J Tonge
Journal:  ACS Infect Dis       Date:  2016-03-07       Impact factor: 5.084

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.